drugset
drugset / Trial / NCT03012360

Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis

NCT03012360 ↗

Phase 4 Terminated 103 enrolled University Hospital, Lille Ministry of Health, France · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

Antimicrobial treatment could be beneficial in patients with ventilator-associated tracheobronchitis (VAT). The hypothesis of this study is that antibiotic treatment for VAT (3 or 7 days), compared with no antibiotic treatment, would reduce the incidence of transition from VAT to ventilator-associated pneumonia (VAP).

Timeline

Start
2018-02-08
Primary completion
2024-07-07
Completion
2024-07-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ceftriaxone Other / unclassified 2 g Intravenous
Subject Ciprofloxacin Small molecule 400 mg Intravenous
Subject IMIPENEM ANHYDROUS Small molecule 1 g Intravenous
Subject Linezolid Other / unclassified 600 mg Intravenous

Indications

No indication recorded.